Regeneron Secures $40M Radiopharma Pact with Telix and Gains Pediatric EU Approval for Dupixent
Regeneron and Telix will co-develop radiopharmaceutical therapies in a 50/50 profit-sharing deal, with Telix receiving a $40M upfront payment for four programs and up to $2.1B in milestones and royalties. The European Commission approved Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2-11, marking its fourth pediatric approval.
1. Collaboration with Telix for Radiopharmaceuticals
Regeneron and Telix entered a 50/50 cost and profit-sharing agreement to co-develop next-generation radiopharmaceutical therapies. Under the deal, Telix receives $40 million upfront for four initial programs and may earn up to $2.1 billion in development and commercial milestones plus royalties, with options to expand the collaboration to additional targets. The partnership leverages Regeneron’s antibody discovery platforms and Telix’s radiopharmaceutical manufacturing expertise, and includes joint development of radio-diagnostics to guide patient selection and treatment response.
2. EU Approval Expands Dupixent Pediatric Indications
The European Commission has approved Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11, based on the LIBERTY-CUPID program demonstrating significant urticaria activity reduction versus placebo. This approval marks Dupixent’s fourth pediatric indication for type 2 inflammation-driven diseases, broadening Regeneron’s market in pediatric dermatology and reinforcing Dupixent’s role as a leading targeted biologic.